O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-2.08%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$10.7B
AUM Growth
+$10.7B
(-6.6%)
Cap. Flow
+$450M
Cap. Flow
% of AUM
4.22%
Top 10 Holdings %
Top 10 Hldgs %
33.33%
Holding
184
New
34
Increased
39
Reduced
24
Closed
28
Top Buys
| 1 |
Edgewise Therapeutics
EWTX
|
$453M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
$121M |
| 3 |
Haemonetics
HAE
|
$94.6M |
| 4 |
Terns Pharmaceuticals
TERN
|
$83.4M |
| 5 |
IMA
ImageneBio, Inc. Common Stock
IMA
|
$82.9M |
Top Sells
| 1 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
$319M |
| 2 |
Prelude Therapeutics
PRLD
|
$241M |
| 3 |
Pfizer
PFE
|
$133M |
| 4 |
Biogen
BIIB
|
$125M |
| 5 |
Centene
CNC
|
$120M |
Sector Composition
| 1 | Healthcare | 95.15% |
| 2 | Technology | 0.12% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $455M | 4.26% | 6,186,307 -1,220,000 | -16% | -$89.8M |
|
|
2
Edgewise Therapeutics
EWTX
$1.51B
| $453M | 4.24% | +13,944,680 | New | +$453M |
|
|
3
Prelude Therapeutics
PRLD
$68.5M
| $435M | 4.07% | 10,039,691 -5,555,186 | -36% | -$241M |
|
4
ARS Pharmaceuticals
SPRY
$1.15B
| $381M | 3.57% | 8,740,887 | – | – |
|
|
HZNP
5
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $289M | 2.71% | 3,144,355 +135,600 | +5% | +$12.5M |
|
6
Merck
MRK
$210B
| $288M | 2.69% | 3,732,400 +1,073,100 | +40% | +$82.7M |
|
7
Bristol-Myers Squibb
BMY
$96B
| $285M | 2.67% | 4,515,400 +966,300 | +27% | +$61M |
|
8
AbCellera Biologics
ABCL
$1.25B
| $278M | 2.6% | 8,200,768 -200,000 | -2% | -$6.79M |
|
9
Boston Scientific
BSX
$156B
| $267M | 2.5% | 6,920,600 +397,600 | +6% | +$15.4M |
|
10
Vertex Pharmaceuticals
VRTX
$100B
| $244M | 2.28% | 1,135,900 +301,800 | +36% | +$64.9M |
|
11
PMV Pharmaceuticals
PMVP
$74.2M
| $241M | 2.25% | 7,330,423 | – | – |
|
|
TPTX
12
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $223M | 2.09% | 2,361,327 -384,000 | -14% | -$36.3M |
|
13
Natera
NTRA
$23.1B
| $223M | 2.08% | 2,195,900 +85,200 | +4% | +$8.65M |
|
14
Iovance Biotherapeutics
IOVA
$807M
| $210M | 1.97% | 6,645,100 | – | – |
|
|
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $209M | 1.96% | 1,221,200 +75,900 | +7% | +$13M |
|
16
Arcutis Biotherapeutics
ARQT
$1.86B
| $176M | 1.64% | 6,073,850 | – | – |
|
17
Xtant Medical Holdings
XTNT
$83.3M
| $172M | 1.61% | 72,873,494 +70,422 | +0.1% | +$166K |
|
18
UnitedHealth
UNH
$281B
| $150M | 1.4% | 403,000 +12,700 | +3% | +$4.73M |
|
19
Guardant Health
GH
$8.41B
| $149M | 1.4% | 977,400 +439,200 | +82% | +$67M |
|
20
Humana
HUM
$36.5B
| $131M | 1.23% | 313,600 +27,500 | +10% | +$11.5M |
|
21
AbbVie
ABBV
$372B
| $131M | 1.23% | 1,213,200 +350,900 | +41% | +$38M |
|
22
Theravance Biopharma
TBPH
$699M
| $127M | 1.19% | 6,219,110 | – | – |
|
23
Neurocrine Biosciences
NBIX
$13.8B
| $127M | 1.18% | 1,301,715 | – | – |
|
24
Passage Bio
PASG
$22.7M
| $122M | 1.14% | 6,962,899 | – | – |
|
|
GRCL
25
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $121M | 1.14% | +7,884,870 | New | +$121M |
|